Zobrazeno 1 - 10
of 702
pro vyhledávání: '"Dick De Zeeuw"'
Autor:
J. David Smeijer, Donald E. Kohan, Peter Rossing, Ricardo Correa-Rotter, Adrian Liew, Sydney C.W. Tang, Dick de Zeeuw, Ron T. Gansevoort, Wenjun Ju, Hiddo J. Lambers Heerspink
Publikováno v:
Cardiovascular Diabetology, Vol 22, Iss 1, Pp 1-9 (2023)
Abstract Background Insulin resistance (IR) is a pathophysiologic hallmark of type 2 diabetes and associated with the presence of chronic kidney disease (CKD). Experimental studies suggest that endothelin-1 increases IR. We assessed the association b
Externí odkaz:
https://doaj.org/article/5a8a0515db9b45b0b507829cb5bcedce
Autor:
Bernard Zinman, Bruce Neal, George L Bakris, Vlado Perkovic, Meg J Jardine, Kris Rogers, Jie Yu, Adeera Levin, Dick de Zeeuw, Hong Zhang, Kenneth W Mahaffey, Clare Arnott, Rajiv Agarwal, Gian Luca Di Tanna, Carol Pollock, David C Wheeler, Christopher P Cannon, David M Charytan, Hiddo J Lambers Heerspink, Norman Rosenthal
Publikováno v:
BMJ Open Diabetes Research & Care, Vol 11, Iss 3 (2023)
Introduction Relationships between glycemic-lowering effects of sodium glucose co-transporter 2 inhibitors and impact on kidney and cardiovascular outcomes are uncertain.Research design and methods We analyzed 4395 individuals with prebaseline and po
Externí odkaz:
https://doaj.org/article/83663dfd99b5429482efb801e4aa82d8
Autor:
Jing‐Wei Li, Clare Arnott, Hiddo J. L. Heerspink, Qiang Li MBiostat, Christopher P. Cannon, David C. Wheeler, David M. Charytan, Jennifer Barraclough, Gemma A. Figtree, Rajiv Agarwal, George Bakris, Dick de Zeeuw, Tom Greene, Adeera Levin, Carol Pollock, Hong Zhang, Bernard Zinman, Kenneth W. Mahaffey, Vlado Perkovic, Bruce Neal, Meg J. Jardine
Publikováno v:
Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, Vol 11, Iss 16 (2022)
Background The sodium‐glucose cotransporter 2 inhibitor canagliflozin reduced the risk of first cardiovascular composite events in the CREDENCE (Canagliflozin and Renal Events in Diabetes With Established Nephropathy Clinical Evaluation) trial. In
Externí odkaz:
https://doaj.org/article/46cbfff7ef724eea8154c25524ea230a
Autor:
Kim M. Gooding, Chrysta Lienczewski, Massimo Papale, Niina Koivuviita, Marlena Maziarz, Anna-Maria Dutius Andersson, Kanishka Sharma, Paola Pontrelli, Alberto Garcia Hernandez, Julie Bailey, Kay Tobin, Virva Saunavaara, Anna Zetterqvist, David Shelley, Irvin Teh, Claire Ball, Sapna Puppala, Mark Ibberson, Anil Karihaloo, Kaj Metsärinne, Rosamonde E. Banks, Peter S. Gilmour, Michael Mansfield, Mark Gilchrist, Dick de Zeeuw, Hiddo J. L. Heerspink, Pirjo Nuutila, Matthias Kretzler, Matthew Welberry Smith, Loreto Gesualdo, Dennis Andress, Nicolas Grenier, Angela C. Shore, Maria F. Gomez, Steven Sourbron, for the BEAt-DKD consortium
Publikováno v:
BMC Nephrology, Vol 21, Iss 1, Pp 1-11 (2020)
Abstract Background Diabetic kidney disease (DKD) remains one of the leading causes of premature death in diabetes. DKD is classified on albuminuria and reduced kidney function (estimated glomerular filtration rate (eGFR)) but these have modest value
Externí odkaz:
https://doaj.org/article/e94cbf7fb6ec48ce9d18b5b1e307048f
Autor:
Elisabeth Bakker, Peter G. M. Mol, João Nabais, Thorsten Vetter, Matthias Kretzler, John J. Nolan, Gert Mayer, Anna K. Sundgren, Hiddo J. L. Heerspink, Anja Schiel, Sieta T. de Vries, Maria F. Gomez, Friedrich Schulze, Dick de Zeeuw, Michelle J. Pena, for the BEAt-DKD Consortium
Publikováno v:
Frontiers in Pharmacology, Vol 12 (2021)
Aim: This study aimed to identify from different stakeholders the benefits and obstacles of implementing precision medicine in diabetic kidney disease (DKD) and to build consensus about a way forward in order to treat, prevent, or even reverse this d
Externí odkaz:
https://doaj.org/article/f77b8bd284ea47e89bad5a6ed9657caf
Publikováno v:
Therapeutic Advances in Endocrinology and Metabolism, Vol 12 (2021)
Background: Risk factor-based equations are used to predict risk of kidney disease progression in patients with type 2 diabetes order to guide treatment decisions. It is, however, unknown whether these models can also be used to predict the effects o
Externí odkaz:
https://doaj.org/article/cc83df8a4658427aa06fadba78bcf676
Autor:
Marcus V. B. Malachias, Pardeep S. Jhund, Brian L. Claggett, Magnus O. Wijkman, Rhonda Bentley‐Lewis, Nishi Chaturvedi, Akshay S. Desai, Steven M. Haffner, Hans‐Henrik Parving, Margaret F. Prescott, Scott D. Solomon, Dick De Zeeuw, John J. V. McMurray, Marc A. Pfeffer
Publikováno v:
Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, Vol 9, Iss 19 (2020)
Background NT‐proBNP (N‐terminal pro‐B‐type natriuretic peptide) improves the discriminatory ability of risk‐prediction models in type 2 diabetes mellitus (T2DM) but is not yet used in clinical practice. We assessed the discriminatory stren
Externí odkaz:
https://doaj.org/article/8a476443f76c49ddb55ea83531f84f7a
Autor:
Susanne Eder, Johannes Leierer, Julia Kerschbaum, Laszlo Rosivall, Andrzej Wiecek, Dick de Zeeuw, Patrick B. Mark, Georg Heinze, Peter Rossing, Hiddo L. Heerspink, Gert Mayer
Publikováno v:
Kidney & Blood Pressure Research, Vol 43, Iss 1, Pp 181-190 (2018)
Background/Aims: The prevalence of diabetes mellitus type 2 and kidney disease in these patients varies widely between European countries. Methods: In addition to store bio-samples the “Prospective cohort study in patients with type 2 diabetes mell
Externí odkaz:
https://doaj.org/article/642de6a7606f4d5189a488d306bca805
Autor:
Hans-Joachim Anders, Brad Rovin, David Jayne, Paul Brunetta, Rosanna Coppo, Anne Davidson, Satish Kumar Devarapu, Dick de Zeeuw, Jeremy Duffield, Dirk Eulberg, Alberto Fierro, Jürgen Floege, Steffen Frese, Loïc Guillevin, Stephen Holdsworth, Jeremy Hughes, Ralph Kettritz, Malte Kluger, Christian Krebs, Larissa Lapteva, Adeera Levin, Jinhua Li, Liz Lightstone, Matthias Mack, Ladan Mansouri, Stephen McAdoo, Eoin McKinney, Ulf Panzer, Samir Parikh, Charles Pusey, Chaim Putterman, Ton Rabelink, Andreas Radbruch, Andrew Rees, Mary Reilly, Marlies Reinders, Giuseppe Remuzzi, Piero Ruggenenti, Steven Sacks, Thomas J Schall, Catherine Meyer-Schwesinger, Kumar Sharma, Yusuke Suzuki, Nicola M. Tomas, Ming-Hui Zhao
Publikováno v:
Kidney International Reports, Vol 1, Iss 4, Pp 327-339 (2016)
To date, the treatment of immune-mediated kidney diseases has only marginally benefited from highly specific biological drugs that have demonstrated remarkable effects in many other diseases. What accounts for this disparity? In April 2016, the Inter
Externí odkaz:
https://doaj.org/article/31c0023f19ae480299b2c0347a697892
Publikováno v:
PLoS ONE, Vol 13, Iss 6, p e0199309 (2018)
OBJECTIVE:Urinary albumin:creatinine ratio (UACR) in first morning void (FMV) urine samples collected over three days is the recommended method for measuring and monitoring albuminuria in adults in the clinical setting. Such a guideline is not availa
Externí odkaz:
https://doaj.org/article/0dd63d9c99b6495faf61e907278ddb4c